Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633655 | 1.00 | GRM5 (0.41) | GRM5CHRNB2CHRNA5CHRNA4USP30 | |
| SCHEMBL4076468 | 0.98 | GRM5 (0.40) | GRM5CHRNB2CHRNA5CHRNA4DRD2 | |
| SCHEMBL4076476 | 0.98 | GRM5 (0.40) | GRM5CHRNB2CHRNA5CHRNA4DRD2 | |
| SCHEMBL5631775 | 0.91 | USP30 (0.40) | GRM5CHRNB2CHRNA5CHRNA4USP30 | |
| SCHEMBL5631797 | 0.91 | USP30 (0.40) | GRM5CHRNB2CHRNA5CHRNA4USP30 | |
| SCHEMBL4078277 | 0.88 | GRM5 (0.39) | GRM5CHRNB2CHRNA5CHRNA4USP30 | |
| SCHEMBL4078261 | 0.88 | GRM5 (0.39) | GRM5CHRNB2CHRNA5CHRNA4USP30 | |
| SCHEMBL5630197 | 0.88 | GRM5 (0.46) | GRM5 | |
| SCHEMBL8230979 | 0.88 | GRM5 (0.36) | GRM5 | |
| SCHEMBL5630184 | 0.88 | GRM5 (0.46) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027110-A2 | MGLUR5 MODULATORS III | Astra Zeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130822-A2 | MGLUR5 MODULATORS III | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259926-A1 | mGluR5 modulators III | GRM5, GRM3, GRIK5 | GRM5 1/4885CHRNB2 257/4885CHRNA5 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.